How will the pharma industry fare in 2018 under Trump?

How will the pharma industry fare in 2018 under Trump?

The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.

OPDP issues third enforcement letter of 2017

OPDP issues third enforcement letter of 2017

The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.

Limits on pharma payments to doctors back on policy menu

Limits on pharma payments to doctors back on policy menu

A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.

The FDA issues its second enforcement letter of 2017

The FDA issues its second enforcement letter of 2017

The OPDP has only issued two letters in 2017, compared to 11 last year.

PhRMA criticizes the FDA's research into drug advertising and promotion

PhRMA criticizes the FDA's research into drug advertising and promotion

The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.

Johnson & Johnson in breach of U.K. rules over Nicorette marketing

Johnson & Johnson in breach of U.K. rules over Nicorette marketing

Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.

Bill to allow imported drugs from Canada aims to create competition

Bill to allow imported drugs from Canada aims to create competition

The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.

The FDA attempts to understand how disclosures affect drug ads

The FDA attempts to understand how disclosures affect drug ads

The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.

Astellas reprimanded by U.K. drug regulator

Astellas reprimanded by U.K. drug regulator

The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.

PDUFA amendment would broaden off-label rules

PDUFA amendment would broaden off-label rules

The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.

The FDA cites risk info in letter over Contrave DTC ad

The FDA cites risk info in letter over Contrave DTC ad

The regulator also took issue with how Orexigen Therapeutics presented the risk information

What marketers need to know about tax reform, off-label promotion, pricing

What marketers need to know about tax reform, off-label promotion, pricing

The ad-tax deduction is likely once again on the table.

Califf calls for marketers to develop off-label 'code of ethics'

Califf calls for marketers to develop off-label 'code of ethics'

The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."